AZD3759 inhibits glioma through the blockade of the epidermal growth factor receptor and Janus kinase pathways

References

• Chen R, Smith-Cohn M, Cohen AL, et al. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14(2):284–297.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Stetson L, et al. Epidemiology of gliomas. Cancer Treat Res. 2015;163:1–14.
   PubMedGoogle Scholar
• Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432–446.
   PubMed Web of Science ®Google Scholar
• Liu F, Mischel PS. Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma. Wiley Interdiscip Rev Syst Biol Med. 2018;10(1):10.1002/wsbm.1398.
   PubMed Web of Science ®Google Scholar
• Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5):52. doi: 10.3390/cancers9050052.
   PubMed Web of Science ®Google Scholar
• Rahbarnia L, Farajnia S, Babaei H, et al. Isolation and characterization of a novel human scFv inhibiting EGFR vIII expressing cancers. Immunol Lett. 2016;180:31–38.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Chekhonin IV, Chekhonin VP. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. Eur J Pharmacol. 2017;810:70–82.
   PubMed Web of Science ®Google Scholar
• Sepulveda JM, Sanchez-Gomez P, Vaz Salgado MA, et al. Dacomitinib: an investigational drug for the treatment of glioblastoma. Expert Opin Investig Drugs. 2018;27(10):823–829.
   PubMed Web of Science ®Google Scholar
• Seystahl K, Gramatzki D, Roth P, et al. Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. Expert Opin Pharmacother. 2016;17(9):1259–1270.
   PubMed Web of Science ®Google Scholar
• Akgul S, Patch AM, D’Souza RCJ, et al. Intratumoural heterogeneity underlies distinct therapy responses and treatment resistance in glioblastoma. Cancers (Basel). 2019;11(2):190. doi: 10.3390.
   Web of Science ®Google Scholar
• Roth P, Weller M. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. Neuro Oncol. 2014;16(Suppl 8):viii14–9.
   PubMed Web of Science ®Google Scholar
• Kwatra MM. A rational approach to target the epidermal growth factor receptor in glioblastoma. Curr Cancer Drug Targets. 2017;17(3):290–296.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Wang J, Cheng Z, et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J Med Chem. 2015;58(20):8200–8215.
   PubMed Web of Science ®Google Scholar
• Yang Z, Guo Q, Wang Y, et al. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016;8(368):368ra172.
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Kim DW, Cho BC, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017;5(11):891–902.
   PubMed Web of Science ®Google Scholar
• Rafehi H, Orlowski C, Georgiadis GT, et al. 2011. Clonogenic assay: adherent cells. J Vis Exp. 49. DOI: 10.3791/2573.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Srdic-Rajic T, Konjevic G, et al. TNF-alpha induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol. 2011;239(3):115–122.
   PubMed Web of Science ®Google Scholar
• Lacombe F, Belloc F. Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Hematology and cell therapy. 1996;38(6):495–504.
   PubMedGoogle Scholar
• Jurisic V. Multiomic analysis of cytokines in immuno-oncology. Expert Rev Proteomics. 2020;17(9):663–674.
   PubMed Web of Science ®Google Scholar
• Yeom CJ, Chung JK, Kang JH, et al. Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes. J Nucl Med. 2008;49(9):1489–1497.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ren H, Dai B, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res. 2018;37:324.
   PubMed Web of Science ®Google Scholar
• Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–1061.
   PubMed Web of Science ®Google Scholar
• Lazzari C, Spitaleri G, Catania C, et al. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options. Crit Rev Oncol Hematol. 2014;89(3):358–365.
   PubMed Web of Science ®Google Scholar
• Hirano T, Yasuda H, Tani T, et al. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 2015;6(36):38789–38803.
   PubMed Web of Science ®Google Scholar
• Chao D, Pang L, Shi Y, et al. AZD3759 induces apoptosis in hepatoma cells by activating a p53-SMAD4 positive feedback loop. Biochem Biophys Res Commun. 2019;509(2):535–540.
   PubMed Web of Science ®Google Scholar
• Zhang IY, Zhou H, Liu H, et al. Local and systemic immune dysregulation alters glioma growth in hyperglycemic mice. Clin Cancer Res. 2020;26(11):115–122.
   Web of Science ®Google Scholar
• Wu A, Maxwell R, Xia Y, et al. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. J Neurooncol. 2019;143(2):663–674.
   Web of Science ®Google Scholar
• Huebner D, Rieger C, Bergmann R, et al. An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment. BMC Cancer. 2017;17(1):790.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285:1–24.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109(2):S121–31.
   PubMed Web of Science ®Google Scholar
• Liu L, Nam S, Tian Y, et al. 6-Bromoindirubin-3ʹ-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res. 2011;71(11):3972–3979.
   PubMed Web of Science ®Google Scholar
• Liao J, Xu T, Zheng JX, et al. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. Int J Mol Med. 2013;32(1):79–84.
   PubMed Web of Science ®Google Scholar
• Swiatek-Machado K, Kaminska B. STAT signaling in glioma cells. Adv Exp Med Biol. 2013;986:189–208.
   PubMed Web of Science ®Google Scholar
• Tu Y, Zhong Y, Fu J, et al. Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol. 2011;28(1):15–23.
   PubMed Web of Science ®Google Scholar